MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - February 4, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the eleventh of the Offering, consists of 650,970 Units of the Company (the "
Technology, Healthcare and Hospitals, Health
2026-02-04 6:00 PM EST | MyndTec Inc.
Familywood Launches Canada's Leading Online Clinical Counselling Service for Families Affected by Addiction
Kelowna, British Columbia--(Newsfile Corp. - February 4, 2026) - Familywood proudly announces the launch of its online clinical counselling platform dedicated exclusively to supporting families impacted by addiction. Recognizing that addiction affects entire family systems, not only the individual in recovery, Familywood provides families with accessible, evidence-based therapy to help them heal, reconnect, and learn how to effectively support their loved one's recovery journey.
2026-02-04 4:14 PM EST | Familywood Family Support Services Inc.
Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification. The Form 10, originally filed on December 5, 2025, was not subject to furt
Healthcare and Hospitals, Health
2026-02-04 9:32 AM EST | Adia Nutrition Inc.
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer. To date, 90 patients have been enrol
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-04 7:00 AM EST | Theralase Technologies Inc.
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-03 5:30 PM EST | Medexus Pharmaceuticals Inc.
NewOrg Releases Educational Article on CRM Software for Nonprofits
Washington, D.C.--(Newsfile Corp. - February 3, 2026) - NewOrg has released a new educational article examining the role of CRM software in nonprofit organizations and the key considerations nonprofits should evaluate as their operations evolve. As nonprofits grow, managing information across donors, volunteers, partners, and programs becomes increasingly complex. Many organizations turn to CRM software to centralize relationship data and improve visibility across teams. However, not al
Computer Software, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2026-02-03 3:00 PM EST | NewOrg Management System Inc
Former Miss Universe Canada Delegate Chealse Sophia Howell Sues Grant Cardone and Cardone Capital, Seeking $500 Million in Florida Defamation Case
Miami, Florida--(Newsfile Corp. - February 3, 2026) - Chealse Sophia Howell, former Miss Canada titleholder, Miss Universe Canada delegate, international model, and entrepreneur, has filed a civil lawsuit according to court filings, in the Eleventh Judicial Circuit Court in and for Miami-Dade County, Florida, alleging defamation and tortious interference against Grant Cardone and Cardone Capital, LLC.
Entertainment, Healthcare and Hospitals, Legal
2026-02-03 10:04 AM EST | TMedia Partners
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury sha
Healthcare and Hospitals, Health
2026-02-03 1:10 AM EST | Cosmo Pharmaceuticals N.V.
Discovery Senior Living Appoints Chief Financial Officer
Bonita Springs, Florida--(Newsfile Corp. - February 2, 2026) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., is pleased to announce that Kim Voss will join the Company as Chief Financial Officer, effective February 1, 2026. Voss brings more than two decades of experience leading finance organizations at scale across public company and private equity-owned envi
Healthcare and Hospitals, Real Estate, Housing
2026-02-02 3:12 PM EST | Discovery Senior Living
Adia Nutrition Inc. Announces Dr. Brian Browning as Lead Physician for All Orthopedic Treatments and Specialties at Adia Med
Winter Park, Florida--(Newsfile Corp. - February 2, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, is pleased to announce that Dr. Brian L. Browning, DO, a board-certified expert in family medicine and neuromusculoskeletal medicine, is now the lead physician in charge of all orthopedic treatments and specialties at Adia Med.
Healthcare and Hospitals, Health
2026-02-02 9:00 AM EST | Adia Nutrition Inc.
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully co
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-02 7:00 AM EST | Theralase Technologies Inc.
NuGen Medical Devices Inc. Announces CFO Transition
Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, announces that Veronique Laberge has resigned from her position as Chief Financial Officer and Corporate Secretary. Her resignation is effective January 31, 2026. The Company has appointed Mr. Ajay Mishra as Chief Financial Officer and Corporate Secretary, effective January 31, 2026. Mr. M
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-30 5:15 PM EST | NuGen Medical Devices Inc.
Adia Nutrition Announces Documentary Featuring WWE/TNA Superstar Elias/Elijah Jeff Sciullo's Recovery with Adia Med's AdiaVita Stem Cell Treatment
Winter Park, Florida--(Newsfile Corp. - January 28, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in regenerative therapies, is proud to announce an upcoming documentary chronicling the recovery of professional wrestler Jeff Sciullo—known to fans as Elias in WWE and Elijah in TNA—from a tricep injury sustained in June 2025. The film will focus on his treatment with Adia Med's AdiaVita, a high-potency stem cell product delivering over
Healthcare and Hospitals, Health
2026-01-28 10:00 AM EST | Adia Nutrition Inc.
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnology, Healthcare and Hospitals, Health
2026-01-28 7:03 AM EST | Scryb Inc.
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same da
Healthcare and Hospitals, Health
2026-01-28 1:24 AM EST | Cosmo Pharmaceuticals N.V.
Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered mont
Healthcare and Hospitals, Health
2026-01-26 10:00 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the "Agreement") dated January 20, 2026 with Aquaox LLC ("Aquaox"), a U.S. based manufacturer of environmentally
Technology, Healthcare and Hospitals, Health
2026-01-22 5:00 PM EST | FendX Technologies Inc.
LevelJump Enters into Cooperation Agreement with Concerned Shareholder; Announces Board Reconstitution
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTC Pink: JMPHF) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it has entered into a cooperation agreement (the "Agreement") with Frank Teti. Under the terms of the Agreement, LevelJump has agreed to a reconstitution of its Board of Directors (the "Board") to include new independent perspectives. Effective imm
Healthcare and Hospitals, Health
2026-01-20 4:00 PM EST | LevelJump Healthcare Corp.
Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026
Winter Park, Florida--(Newsfile Corp. - January 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and personalized healthcare, today announced that it has been notified by the U.S. Securities and Exchange Commission (SEC) that its Form 10 registration statement will not be subject to further review. As a result, the Form 10 will automatically become effective 60 days after its original filing date, which is February 3, 2026. The Form 10, originally filed o
Healthcare and Hospitals, Health
2026-01-20 9:30 AM EST | Adia Nutrition Inc.